Genmab to Acquire Merus in $8 Billion Cancer Drug Deal
Denmark's Genmab is acquiring Dutch biotech Merus for approximately $8 billion in a deal that includes a 41% premium over Merus' recent stock price, aiming to expand its pipeline in cancer treatments through this strategic acquisition funded by cash and debt.,